Squawk Pod World Autism Awareness Day 4/3/26
Apr 3, 2026
Christopher Mayle, co-founder of the Autism Impact Fund, invests in life-sciences, diagnostics, services and behavioral health for the neurodiverse community. He discusses the fund’s $150M first close, the need for early capital and better diagnostics, advances in therapeutics and AI, and scaling housing, employment and value-based care to support lifelong independence.
AI Snips
Chapters
Transcript
Episode notes
Private Capital Can Scale Autism Innovation
- The Autism Impact Fund proved private capital can scale autism innovation while delivering market returns.
- Fund One built 17 portfolio companies and two exits, enabling Fund Two's first close and expanded ambition across diagnostics and services.
Autism Is Largely Comorbid Driving Broader Market Needs
- Autism rarely appears alone; roughly 95% of individuals have at least one co-occurring diagnosis.
- That prevalence expands the addressable market into behavioral health, mental health, and complex chronic conditions worth trillions.
Mara Bio Developed A Subtype Blood Test
- Christopher Mayle highlighted Mara Bio as a real-world diagnostic success from AIF's portfolio.
- Mara Bio commercialized a blood test identifying a subtype of autism affecting nearly 20% of diagnosed individuals by detecting maternal antibodies.